Pinnacle Wealth Management Advisory Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.29M Buy
17,031
+964
+6% +$207K 0.26% 84
2026
Q1
$3.49M Sell
16,067
-423
-3% -$93.8K 0.24% 88
2025
Q4
$3.77M Buy
16,490
+90
+0.5% +$20.5K 0.26% 81
2025
Q3
$3.8M Sell
16,400
-85
-0.5% -$17.3K 0.29% 76
2025
Q2
$3.06M Buy
16,485
+1,127
+7% +$209K 0.25% 79
2025
Q1
$3.22M Buy
15,358
+111
+0.7% +$21.6K 0.3% 74
2024
Q4
$2.71M Buy
15,247
+3,947
+35% +$726K 0.25% 79
2024
Q3
$2.23M Buy
11,300
+173
+2% +$32.3K 0.21% 89
2024
Q2
$1.91M Sell
11,127
-125
-1% -$20.7K 0.2% 93
2024
Q1
$2.05M Sell
11,252
-574
-5% -$98.9K 0.22% 89
2023
Q4
$1.83M Sell
11,826
-888
-7% -$129K 0.21% 88
2023
Q3
$1.9M Buy
12,714
+458
+4% +$67.2K 0.25% 85
2023
Q2
$1.65M Sell
12,256
-248
-2% -$36.4K 0.21% 92
2023
Q1
$1.99M Sell
12,504
-1,442
-10% -$220K 0.27% 80
2022
Q4
$2.25M Sell
13,946
-660
-5% -$101K 0.34% 65
2022
Q3
$1.96M Buy
14,606
+2,206
+18% +$317K 0.33% 72
2022
Q2
$1.9M Buy
12,400
+176
+1% +$26.9K 0.31% 78
2022
Q1
$1.98M Buy
12,224
+1,245
+11% +$181K 0.29% 83
2021
Q4
$1.49M Buy
10,979
+2,581
+31% +$305K 0.24% 93
2021
Q3
$906K Sell
8,398
-398
-5% -$45.5K 0.21% 104
2021
Q2
$991K Buy
8,796
+2,000
+29% +$225K 0.23% 97
2021
Q1
$735K Sell
6,796
-40
-0.6% -$4.28K 0.21% 98
2020
Q4
$733K Buy
6,836
+1,182
+21% +$114K 0.22% 94
2020
Q3
$495K Buy
5,654
+785
+16% +$73.9K 0.17% 110
2020
Q2
$478K Buy
4,869
+1,720
+55% +$151K 0.18% 111
2020
Q1
$240K Buy
3,149
+885
+39% +$75.4K 0.12% 136
2019
Q4
$200K Buy
+2,264
New +$188K 0.07% 183
2019
Q2
Sell
-11,747
Closed -$947K 185
2019
Q1
$947K Sell
11,747
-584
-5% -$47.8K 0.43% 73
2018
Q4
$1.14M Buy
12,331
+206
+2% +$18.1K 0.62% 47
2018
Q3
$1.15M Buy
12,125
+566
+5% +$53.7K 0.57% 55
2018
Q2
$1.07M Buy
11,559
+361
+3% +$35.3K 0.58% 54
2018
Q1
$1.06M Sell
11,198
-150
-1% -$16.5K 0.6% 51
2017
Q4
$1.1M Buy
11,348
+61
+0.5% +$5.75K 0.61% 51
2017
Q3
$1M Buy
11,287
+160
+1% +$12.2K 0.58% 58
2017
Q2
$807K Buy
11,127
+1,116
+11% +$75K 0.5% 67
2017
Q1
$652K Buy
10,011
+286
+3% +$18K 0.45% 70
2016
Q4
$609K Buy
9,725
+450
+5% +$27.5K 0.44% 67
2016
Q3
$585K Buy
9,275
+50
+0.5% +$3.24K 0.44% 67
2016
Q2
$571K Buy
9,225
+4,885
+113% +$298K 0.45% 65
2016
Q1
$248K Hold
4,340
0.22% 94
2015
Q4
$257K Sell
4,340
-150
-3% -$8.64K 0.23% 88
2015
Q3
$244K Buy
4,490
+64
+1% +$4.17K 0.24% 82
2015
Q2
$297K Buy
4,426
+1
+0% +$65 0.27% 83
2015
Q1
$259K Hold
4,425
0.23% 91
2014
Q4
$290K Buy
+4,425
New +$279K 0.27% 83

Other funds holding ABBV

Pinnacle Wealth Management Advisory Group's ABBV Position: Q2 2026 in Review

Pinnacle Wealth Management Advisory Group increased its AbbVie (ABBV) stake by 6% in Q2 2026, buying an estimated $207K and bringing the position to 17,031 shares worth $4.29M. The position accounts for 0.26% of the portfolio, ranked #84.

Pinnacle Wealth Management Advisory Group first reported a position in ABBV in Q4 2014 and has held it in 45 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Pinnacle Wealth Management Advisory Group held 17,031 shares of AbbVie worth $4.29M as of Q2 2026.
  • Pinnacle Wealth Management Advisory Group bought 964 AbbVie shares in Q2 2026, an estimated $207K.
  • AbbVie made up 0.26% of Pinnacle Wealth Management Advisory Group's portfolio in Q2 2026, its #84 holding.
  • Pinnacle Wealth Management Advisory Group first reported a position in AbbVie in Q4 2014 and has held it in 45 quarters since.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Pinnacle Wealth Management Advisory Group's 13F filing for Q2 2026, filed 5 Aug 2026.